ArticleThe New England journal of medicine2019
Can Immune Checkpoint Inhibitors Keep JC Virus in Check?
Article in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Rapid-progressing progressive multifocal leukoencephalopathy in two patients newly diagnosed with HIV: case series and review of literature.Journal of neurovirology · 2023Review
- Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab.HemaSphere · 2022Article
- Vitamin D can reduce severity in COVID-19 through regulation of PD-L1.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma.European urology focus · 2021Article
- Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- T cell immunobiology and cytokine storm of COVID-19.Scandinavian journal of immunology · 2021Review
- A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker.Frontiers in immunology · 2021Article
- Coronavirus infection and immune system: An insight of COVID-19 in cancer patients.Critical reviews in oncology/hematology · 2020Review
- Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers.Cancer discovery · 2020Article
- JC Polyomavirus, progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: a review.AIDS research and therapy · 2020Review
- Progressive multifocal leukoencephalopathy after CAR T therapy.International journal of hematology · 2020Article
- On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.Journal for immunotherapy of cancer · 2020Review
- Article
- Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?Annals of translational medicine · 2019Article
- Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML).Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2019Review
- Pembrolizumab as a treatment for PML? Waiting for Godot.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
- Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?Neurology(R) neuroimmunology & neuroinflammation · 2019Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.